Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
This trial has four different groups. You may qualify for one of them:
Group 1 – Sarcoidosis patients without heart inflammation:
- You have been diagnosed with sarcoidosis according to recognised medical guidelines (ATS/ERS criteria) (confirm with trial site)
- You have had a normal 12-lead ECG (heart tracing test) within the past year
- You are a non-smoker
- You have not taken any immune-suppressing medications for at least one year
Group 2 – Sarcoidosis patients with signs of active heart inflammation:
- You have been diagnosed with sarcoidosis according to recognised medical guidelines (ATS/ERS criteria) (confirm with trial site)
- A recent heart MRI or PET scan has shown signs of active inflammation in your heart
- You are a non-smoker
Group 3 – People who have recently had a heart attack (STEMI):
- Your heart attack was confirmed by a specific pattern on a heart tracing test (ECG)
- Your symptoms started within the last 12 hours
- You are currently receiving a heart procedure to treat an acute blockage
- You are able to give consent for a blood draw
Group 4 – Healthy volunteers:
- You have no known heart disease
- You do not have high blood pressure or diabetes
- You are a non-smoker
Who may not be able to join:
Group 1:
- You have a known heart condition
- You currently smoke
- You are currently taking immune-suppressing medications
Group 2:
- You have a known heart condition other than sarcoidosis
- You currently smoke
- You are currently taking immune-suppressing medications
Group 3:
- You currently smoke
- Your condition is medically unstable at the time of the study (confirm with trial site)
Group 4:
- No specific exclusion criteria listed beyond not meeting the inclusion requirements above (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nabeel Hamzeh, MD, University of Iowa
Phone: 319-353-8862
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
cfDNA level
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.